Source of citations
to research studies: |
In this issue of INFO Reports the citations to research studies come from systematic reviews conducted on behalf of the WHO Secretariat for the October 2003 Expert Working Group meeting. The Expert Working Group considered this evidence in reaching its decisions about medical eligibility criteria.
In general, these systematic reviews selected reports that were:
- Found through searches of MEDLINE, PREMEDLINE, POPLINE, and/or similar bibliographic databases;
- Published in peer-reviewed journals between 1966, in most cases, and August 2003; and
- Reported studies, systematic reviews of studies, or meta-analyses that examined health outcomes associated with use of a contraceptive method among women with a specified health condition.
Kate Curtis, PhD, and Anshu Mohllajee, MPH, of the US Centers for Disease Control and Prevention; Kavita Nanda, MD, MHS, of Family Health International; Lori Bastian, MD, MPH, of Duke University; Mary E. Gaffield, MPH, PhD, of WHO; and Jennifer S. Smith, PhD, MPH, of the International Agency for Research on Cancer, conducted these systematic reviews.
|
Bibliography
1. BRISSON, J., MORIN, C., FORTIER, M., ROY, M., BOUCHARD, C., LECLERC, J., CHRISTEN, A., GUIMONT, C., PENAULT, F., and MEISELS, A. Risk factors for cervical intraepithelial neoplasia: Differences between low- and high-grade lesions. American Journal of Epidemiology 140(8): 700-710. 1994.
2. BRITISH MEDICAL ASSOCIATION. Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on Heterosexual Transmission of HIV. British Medical Journal 304: 809-813. 1992.
3. CARAEL, M., VAN DE PERRE, P.H., LEPAGE, P.H., ALLEN, S., NSENGUMUREMYI, F., VAN GOETHEM, C., NTAHORUTABA, M., NZARAMBA, D., and CLUMECK, N. Human immunodeficiency virus transmission among heterosexual couples in Central Africa. AIDS 2(3): 201-205. 1988.
4. CONNOR, P.D., TAVERNIER, L.A., THOMAS, S.M., GATES, D., and LYTTON, S.M. Determining risk between Depo-Provera use and increased uterine bleeding in obese and overweight women. Journal of the American Board of Family Practice 15(1): 7-10. Jan-Feb. 2002.
5. CROMER, B., SMITH, R., BLAIR, J., DWYER, J., and BROWN, R. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxy progesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 94(5): 687-694. 1994.
6. DEIGEN, J., DUYN, K., JANSEN, W., and KLITSIE, J. Use of monophasic, low-dose oral contraceptive in relation to mental functioning. Contraception 46(4): 359-367. 1992.
7. DUGGAN, M.A., MCGREGOR, S.E., STUART, G.C., MORRIS, S., CHANG-POON, V., SCHEPANSKY, A., and HONORE, L. The natural history of CIN I lesions. European Journal of Gynaecological Oncology 19(4): 338-344. 1998.
8. GUPTA, N., O'BRIEN, R., JACOBSEN, L.J., DAVIS, A., ZUCKERMAN, A., SUPRAN, S., and KULIG, J. Mood changes in adolescents using depot-medroxyprogesterone acetate for contraception: A prospective study. Journal of Pediatric and Adolescent Gynecology 14(2): 71-76. May 2001.
9. HELMS, S.E., BREDLE, D.L., ZAJIC, J., JARFOURA, D., RODELL, R.T., and KRISHNARAO, I. Oral contraceptive failure rates and oral antibiotics. Journal of the American Academy of Dermatology 36(5): 5-10. 1997.
10. HERZBERG, B.N., DRAPER, K.C., JOHNSON, A.L., and NICOL, G.C. Oral contraceptives, depression, and libido. British Medical Journal 3(773): 495-500. 1971.
11. HO, G.Y., BURK, R.D., KLEIN, S., KADISH, A.S., CHANG, C.J., PALAN, P., BASU, J., TACHEZY, R., LEWIS, R., and ROMNEY, S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. Journal of the National Cancer Institute 87(18): 1365-1371. Sep. 1995.
12. HUGHES, B.R. and CUNLIFFE, W.J. Interactions between the oral contraceptive pill and antibiotics. [Comment]. British Journal of Dermatology 122(5): 717-718. 1990.
13. JOSHI, J.V., JOSHI, U.M., SANKHOLI, G.M., KRISHNA, U., MANDLEKAR, A., CHOWDHURY, V., HAZARI, K., GUPTA, K., SHETH, U.K., and SAXENA, B.N. A study of interaction of low-dose combination oral contraceptive with Ampicillin and Metronidazole. Contraception 22(6): 643-652. Dec. 1980.
14. KAPIGA, S.H., LYAMUYA, E.F., LWIHULA, G.K., and HUNTER, D.J. The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS 12(1): 75-84. Jan. 1998.
15. KAPIGA, S.H., SHAO, J.F., LWIHULA, G.K., and HUNTER, D.J. Risk factors for HIV infection among women in Dar-es-Salaam, Tanzania. Journal of Acquired Immune Deficiency Syndromes 7(3): 301-309. Mar. 1994.
16. KJAER, S.K., ENGHOLM, G., DAHL, C., BOCK, J.E., LYNGE, E., and JENSEN, O.M. Case-control study of risk factors for cervical squamous-cell neoplasia in Denmark. III. Role of oral contraceptive use. Cancer Causes Control 4(6): 513-519. 1993.
17. KOKE, S., BROWN, E., and MINER, C. Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. American Journal of Obstetrics and Gynecology 187(3): 551-555. 2002.
18. LARSSON, B. and WENNERGREN, M. Investigation of a copper-intrauterine device (Cu-IUD) for possible effect on frequency and healing of pelvic inflammatory disease. Contraception 15: 143-149. 1977.
19. LEIMAN, G. Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure. American Journal of Obstetrics and Gynecology 114(1): 97-102. Sep. 1972.
20. LONDON, B. and LOOKINGBILL, D. Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives. Archives of Dermatology 130(3): 392-393. 1994.
21. MANGAN, S.A., LARSEN, P.G., and HUDSON, S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. Journal of Pediatric and Adolescent Gynecology 15(2): 79-82. Apr. 2002.
22. MANN, J.M., NZILAMBI, N., PIOT, P., BOSENGE, N., KALALA, M., FRANCIS, H., COLEBUNDERS, R.C., AZILA, P.K., CURRAN, J.W., and QUINN, T.C. HIV infection and associated risk factors in female prostitutes in Kinshasa, Zaire. AIDS 2(4): 249-254. Aug. 1988.
23. MARTIN, H.L., JR., NYANGE, P.M., RICHARDSON, B.A., LAVREYS, L., MANDALIYA, K., JACKSON, D.J., NDINYA-ACHOLA, J.O., and KREISS, J. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. The Journal of Infectious Diseases 178(4): 1053-1059. Oct. 1998.
24. MATI, J.K., HUNTER, D.J., MAGGWA, B.N., and TUKEI, P.M. Contraceptive use and the risk of HIV infection in Nairobi, Kenya. International Journal of Gynaecology and Obstetrics 48(1): 61-67. Jan. 1995.
25. MAYER, K., POBLETE, R., HATHAWAY, B., PALIC, B., PILSON, R., SIEMON-HRYCZYK, P., and DECAPRARIIS, R. Efficacy, effect of oral contraceptives and adherence in HIV infected women receiving Fortovase (Saquinavir) soft gel capsule (SQV-SGC; FTV) thrice (TID) and twice (BID) daily regimens. Presented at the XIII International AIDS Conference, Durban, 2000. (Available: <http://www.iac2000.org/abdetail.asp?ID=TuPeB3226>, Accessed Feb. 20, 2004)
26. MILDVAN, D., YARRISH, R., MARSHAK, A., HUTMAN, H.W., MCDONOUGH, M., LAMSON, M., and ROBINSON, P. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. Journal of Acquired Immune Deficiency Syndromes 29(5): 471-477. Apr. 2002.
27. MORENO, V., BOSCH, F.X., MUNOZ, N., MEIJER, C.J., SHAH, K.V., WALBOOMERS, J.M., HERRERO, R., and FRANCESCHI, S. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC multicentric case-control study. Lancet 359(9312): 1085-1092. 2002.
28. MORRISON, C.S., SEKADDE-KIGONDU, C., MILLER, W.C., WEINER, D.H., and SINEI, S.K. Use of sexually transmitted disease risk assessment algorithms for selection of intrauterine device candidates. Contraception 59(2): 97-106. Feb. 1999.
29. MORRISON, C.S., SEKADDE-KIGONDU, C., SINEI, S.K., WEINER, D.H., KWOK, C., and KOKONYA, D. Is the intrauterine device appropriate contraception for HIV-1-infected women? British Journal of Obstetrics and Gynaecology 108(8): 784-790. 2001.
30. MOSTAD, S.B., OVERBAUGH, J., DEVANGE, D.M., WELCH, M.J., CHOHAN, B., MANDALIYA, K., NYANGE, P., MARTIN, H.L., JR., NDINYA-ACHOLA, J., BWAYO, J.J., and KREISS, J.K. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 350(9082): 922-927. Sep. 1997.
31. NANDA, K. Hormonal contraceptive use in women treated with antiretroviral drugs. Presented at the Expert Working Group meeting to update the "Medical eligibility criteria for contraceptive use", Geneva, Oct 21-24, 2003. Family Health International (FHI).
32. NANDA, K. Progestin-only contraceptives in lactating women < 6 weeks postpartum. [Systematic Review]. Presented at the Expert Working Group meeting to update the "Medical eligibility criteria for contraceptive use", Geneva, Oct 21-24, 2003. Family Health International (FHI).
33. NANDA, K. and BASTIAN, L. Hormonal contraception in women with depression. Presented at the Expert Working Group meeting to update the "Medical eligibility criteria for contraceptive use", Geneva, Oct 21-24, 2003. Family Health International (FHI).
34. NEGRINI, B.P., SCHIFFMAN, M.H., KURMAN, R.J., BARNES, W., LANNOM, L., MALLEY, K., BRINTON, L.A., DELGADO, G., JONES, S., TCHABO, J.G., and ET AL. Oral contraceptive use, human papillomavirus infection, and risk of early cytological abnormalities of the cervix. Cancer Research 50(15): 4670-4675. Aug. 1990.
35. NICOLOSI, A., CORREA LEITE, M.L., MUSICCO, M., ARICI, C., GAVAZZENI, G., and LAZZARIN, A. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: A study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology 5(6): 570-575. Nov. 1994.
36. OUELLET, D., HSU, A., QIAN, J., LOCKE, C.S., EASON, C.J., CAVANAUGH, J.H., LEONARD, J.M., and GRANNEMAN, G.R. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. British Journal of Clinical Pharmacology 46(2): 111-116. Aug. 1998.
37. PLOURDE, P.J., PLUMMER, F.A., PEPIN, J., AGOKI, E., MOSS, G., OMBETTE, J., RONALD, A.R., CHEANG, M., D'COSTA, L., and NDINYA-ACHOLA, J.O. Human immunodeficiency virus type 1 infection in women attending a sexually transmitted diseases clinic in Kenya. Journal of Infectious Diseases 166(1): 86-92. Jul. 1992.
38. RICHARDSON, B.A., MORRISON, C.S., SEKADDE-KIGONDU, C., SINEI, S.K., OVERBAUGH, J., PANTELEEFF, D.D., WEINER, D.H., and KREISS, J.K. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS 13(15): 2091-2097. Oct. 1999.
39. SINEI, S.K., FORTNEY, J.A., KIGONDU, C.S., FELDBLUM, P.J., KUYOH, M., ALLEN, M.Y., and GLOVER, L.H. Contraceptive use and HIV infection in Kenyan family planning clinic attenders. International Journal of STD & AIDS 7(1): 65-70. 1996.
40. SINEI, S.K., MORRISON, C.S., SEKADDE-KIGONDU, C., ALLEN, M., and KOKONYA, D. Complications of use of intrauterine devices among HIV-1-infected women. Lancet 351(9111): 1238-1241. Apr. 1998.
41. SMITH, J.S., GREEN, J., BERRINGTON DE GONZALEZ, A., APPLEBY, P., PETO, J., PLUMMER, M., FRANCESCHI, S., and BERAL, V. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361(9364): 1159-1167. Apr. 2003.
42. SODERBERG, G. and LINDGREN, S. Influence of an intrauterine device on the course of an acute salpingitis. Contraception 24: 137-143. 1981.
43. SPENCE, M.R., ROBBINS, S.M., POLANSKY, M., and SCHABLE, C.A. Seroprevalence of human immunodeficiency virus type I (HIV-1) antibodies in a family-planning population. Sexually Transmitted Diseases 18(3): 143-145. 1991.
44. TACKETT, D., CHILD, M., AGARWALA, S., GEIGER, M., GERALDES, M., and O'MARA, E. Atazan avir: A summary of two pharmacokinetic drug interaction studies in healthy subjects. [Abstract]. Presented at the 10th Retrovirus Conference, Boston, MA, Feb. 10-14, 2003. (Available: <http://www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID=649>, Accessed Feb. 20, 2004)
45. TEISALA, K. Removal of an intrauterine device and the treatment of acute pelvic inflammatory disease. Annals of Medicine 21(1): 63-65. Feb.1989.
46. THOMAS, D.B., YE, Z., and RAY, R.M. Cervical carcinoma in situ and use of depot-medroxyprogesterone acetate (DMPA). WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception 51(1): 25-31. 1995.
47. VAN DAMME, L., RAMJEE, G., ALARY, M., VUYLSTEKE, B., CHANDEYING, V., REES, H., SIRIVONGRANGSON, P., MUKENGE-TSHIBAKA, L., ETTIEGNE-TRAORE, V., UAHEOWITCHAI, C., KARIM, S.S., MASSE, B., PERRIENS, J., and LAGA, M. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360(9338): 971-977. 2002.
48. WESTHOFF, C., TRUMAN, C., KALMUSS, D., CUSHMAN, L., DAVIDSON, A., RULIN, M., and HEARTWELL, S. Depressive symptoms and Depo-Provera. Contraception 57(4): 237-240. Apr. 1998.
49. WILKENSON, D., RAMJEE, G., THOLANDI, M., and RUTHERFORD, G. Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men (Cochrane Review). The Cochrane Library (3). Oxford, Update Software. 2003.
50. WILKENSON, D., THOLANDI, M., RAMJEE, G., and RUTHERFORD, G.W. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: Systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infectious Diseases 2: 613-617. Oct. 2002.
51. WORLD HEALTH ORGANIZATION (WHO). Improving access to quality care in family planning: Medical eligibility criteria for contraceptive use. 2nd ed. Geneva, WHO, 2001.
52. WORLD HEALTH ORGANIZATION (WHO). Selected practice recommendations for contraceptive use. Geneva, WHO Department of Reproductive Health and Research, 2002. 94 p.
53. WORLD HEALTH ORGANIZATION (WHO). Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach. [Revision Draft]. Geneva, 2003. 44 p. (Available: <http://www.who.int/hiv/pub/prev_care/en/WHO_ARV_Guidelines_Update.pdf>, Accessed Feb. 20, 2004)
54. WORLD HEALTH ORGANIZATION (WHO). Treating 3 million by 2005: making it happen: the WHO strategy: the WHO and UNAIDS global initiative to provide antiretroviral therapy to 3 million people with HIV/AIDS in developing countries by the end of 2005. Geneva, WHO, 2003. (Available: <http://www.who.int/3by5/publications/documents/en/Treating3millionby2005.pdf>, Accessed Feb. 20, 2004)
55. WORLD HEALTH ORGANIZATION (WHO). Summary Tables. [3rd ed. Draft]. In: Improving access to quality care in family planning: Medical eligibility criteria for contraceptive use. Geneva, Nov. 2003.
|
